Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gotta say I have enjoyed it since first investing in 2011. The transparency has been a refreshing change from most of my investments, it's been great to be informed and treated like a dedicated shareholder. The complainers will complain regardless of what style he chooses, "he says too much, he doesn't say enough, whaa whaa blah blah". Keep up the great progress team CTIX!
It's fine, the point has been made for those willing to be objective, so again... let's move on. Presentation should be going, wish I was there!
Your examples didn't pan out? Sox provided a list of over 150 companies, everyone else gave one or two examples that fit their agenda, LOL!!!
Just added to my position today as well. Now we need what is looking like a good growth quarter to turn into a nice acceleration of increasing revenue, so far so good...
Don't get so worked up on my post ending in we shall see - maybe you need something from your doctor?
With increasing sales and data in their last quarterly, 7 million cash on hand, looks like they'll need to raise capital in... wait, even if sales weren't going to increase they could operate for at least a year, but if sales increase (and yes, companies are known to make sales advances overseas without selling in the US) then the amount of dilution needed is tiny to none. But, we shall see...
The new board member?
CTIX is probably one of the safest places to be right now, if you still want your money to have potential upside. Low beta, lots of upcoming catalysts.
Regardless of the potential truth or falsehood of those statements, some would like people to believe CTIX is in the same category as the bottom 90% of startup biotechs. Of course CTIX is much more than the typical one hit wonder, having advanced stage trials starting for an impressive number of separate indications using three completely unrelated compounds. Until we see verifiable numbers to the accusations it continues to be the typical hyperbolic BS.
I think that what they do know is that pumping in Kevetrin at extremely high doses once a week is not advantageous based upon the pharmacodynamic analyses they have performed. The investigators have realized that maintaining concentrations in the bloodstream for extended periods is what patients need and a smaller dose more times per week will accomplish this. It is a waist of time and resources to continue the current protocol - time for phase 2 trials with better dosing regimines knowing what they know now with Phase 1 data in hand. People need to stop thinking in straight lines.
This is so hilarious! Every single dose administered was tolerated, thus no high grade serious adverse events resulted in ceasing the dose escalation. Therefore, the maximum tolerated dose was the maximum administered dose. Dude! This is not as complicated as resolving magnetic recombinations in the solar corona - it's pretty darn simple: Kevetrin has been an enormous success and we're all just awaiting the official trial ending announcement. It's going to be glorious!
Andy, it matters - I appreciate it and enjoy reading what I consider to be some meaningful foreshadowing of great success. Thank you.
Good point! Some tend to focus on progress and the future, some tend to dwell and regurgitate the past. I'm going to focus on Cellceutix's future to inform my investment approach - nothing but trial success to date, and nothing but trial success expected based on press released info, orphan drug designations, etc.
I guess we'll have to wait for the trial design to be announced, however biodoc is correct that the 750mg/m2 dose in Phase I would be considered larger than the efficacy in the mice studies. The FDA guidance document from FDA.gov lists the conversion number for mg/kg to mg/m2 in mice at 3 ( 200mg/kg = 600mg/m2 for mice). They also list Human Equivalent Dose (HED) conversions, Mouse to HED for mg/kg is 0.08 so 200mg/kg mouse is 16mg/kg human. Converting 16mg/kg human back to mg/m2 is 592mg/m2 human, as compared to the 750mg/m2 dose in the Phase I.
Take this all as estimates, but numbers are from the FDA's 'Guidance for Industry' document.
Ah shoot, that's correct - I somehow attributed the 200mg/kg to the dosage chosen for the trial, but the PR does mention this as a mouse dose. Throw my math out the window - thanks for catching that
Neither is the market - if everyone was proficient at calculating results, Cellceutix would be worth much much more. Luckily we have plenty of time and money (if you do the math on information in the quarterly filings) for the market to figure it out themselves or for trial results to be spoon fed to the market. Soon enough one or the other will happen. Cheers
Well, a 150 lbm person about 5ft6inches tall has a Body Surface Area (BSA) of about 1.78 m2 and 150lbm=68kg. So converting 200mg/kg would go 200mg/kg * 68kg / 1.78m2 = 7640mg/m2. This must be the total dose over the several days of Kevetrin infusions (10 days of 764mg/m2 or 20 days of 382mg/m2). But convert back to the proper units - 20 days of 10mg/kg dosing is a total 200mg/kg dosage. Think I did that math correctly...
I think you may have confused 200mg/kg with 750mg/m2(the final dose in the phase I). 200mg/kg is larger than you think (e.g. with respect to a 30mg/kg docetaxel dose)
Agreed, trying to take the maximum allowed $3k reduction to your AGI to save a few tens of dollars on your tax bill is definitely not worth missing the potential much larger gains - Cellceutix does have a history of massive year end gains!
The latest news listed on sanofi's site lists collaborations with Regeneron for a couple of drugs. Doesn't Leo refer to taking Cellceutix on a similar corporate trajectory as Regeneron? Just a fun coincidence... or is it... Haha
Better complete taxloss selling before $4, LOL Else you'd end up making too much money on this stock. :-P
I hope no one was waiting for $0.70 ahhhh ha ha ha
The legendary CTIX holiday run has begun, perhaps?
I agree! We have enough cash to see three trials complete before any more shares are sold. Two of these are phase 2 trials. Once these three trials complete, share sales will occur at much higher share prices - smooth sailing.
Cash balance will easily take us through completion of Kevetrin Phase I, Prurisol, and Brilacidin OM - allowing the share price to appreciate significantly. Almost the full $30M remaining from Aspire. Finances are as good as I hoped, cash remaining is even a bit more than I had expected. Burn rate was half this quarter from what it was a year ago. Looking good CTIX!
Correct, the redaction was only for the public release, Rosen received the entire letter free of redactions. It really makes one wonder how juicy is the information in the redacted paragraphs?
It was provided to Rosen, and likely in the non redacted form, but due to potential legal proceedings, the redacted information was not meant for our eyes.
If anyone has been committing securities fraud, they better have done it from deep in the shadows because we all know about Ashcroft Firm's relationship with the SEC. Boots be a shakin!
My favorite section:
Great post kelt! It's no secret what goes on here.
We agree. Just saying that the headline excluding 'and secondary' is likely to arrive 6 months minus 4 weeks (5 months) sooner... and be quite well received as well.
Because "in the boardroom to the executives of" would have given away too much information, duh.
Since the only "up to 6 months" timeframe in the primary outcome measures is Maximum Tolerated Dose (MTD) and we're already finishing the final Max Administered Dose (MAD) cohorts, I figure the "up to 4 weeks" timeframe of Dose Limiting Toxicity (DLT) is the only active primary at this point. I kind of expect our CEO to announce that "Kevetrin has successfully met all primary endpoints in the Phase I study at Dana Farber" by end of 2015. Then, up to 6 months later the study will have data on all secondary endpoints.
First of all, polymedix did not go under due to Brilacidin's success, they went under due to a different drug they had in development failing. And I absolutely attribute our trial successes to the brilliance of our management and scientific staff in properly defining trial protocols and all of the successful interaction with regulatory officials as validated by our QIDP designation and the recent Orphan drug for ovarian cancer with Kevetrin. It is absolutely the direct result of how our company has been managed and it is why I continue to invest with Cellceutix.
Well put - if one's metric for performance is stock price, then you've selected one of the most irrelevant arguing points about future success. This is obvious when looking at relative volatility in the biotech sector and anyone who is doom and gloom about a biotech company being temporary down 70% from historical highs has not been investing long or is trying to promote unreasonable fear. Anyone can research past price performance of big names like PCYC, JAZZ, etc. and see periods of 70% off past highs - ultimately it is trial success that effect future price and CTIX's trial record is 100% success on three so far, 2 more in progress and a third, a Phase 3 with high probability of enormous success, about to begin. The stock price will follow, who cares if we're at this current price for now? Relax and enjoy reading the science on www.cellceutix.com - lots there to digest.
I just wasn't sure if I had read that Brilacidin 'has' anti-inflammatory properties verses 'hoping to discover it has' anti-inflammatory properties. I'd be A-OK learning that Brilacidin did indeed have all the anti-inflammatory properties we all hope it has...
I thought this was interesting:
Haha - good point, cell cycle regulator genes won't be the first to be spliced, much bigger splicing market just waiting to be tapped - race is on now that it's first to file.
Walk in for a cancer treatment, walk out in the process of growing a trunk - could be cool!
"Uh... sorry, we uh... spliced the wrong gene."
It would be amazing if down the road a longterm study was performed to show Kevetrin actually reduced one's chance of getting cancer when taken regularly. Imagine the sales numbers! Haha - long way off, luckily we won't be waiting long for a load of phase 2/3s to start bringing on major share price appreciation.
Sounds as if their claims probably relate to elephant genes, whereas Cellceutix's already granted patent is dealing with human genes. I'm not a biologist, but I'm guessing splicing elephant p53 into human DNA has a few hurdles associated with technical feasibility and/or ethical feasibility.